Síndrome da lise tumoral

Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004 Oct;127(1):3-11.Texto completo  Resumo

Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med. 1993 Feb;94(2):133-9. Resumo

Montesinos P, Lorenzo I, Martin G, et al. Tumour lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008 Jan;93(1):67-74.Texto completo  Resumo

Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004 Apr 15;116(8):546-54. Resumo

Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010 May;149(4):578-86.Texto completo  Resumo

Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011 May 12;364(19):1844-54. Resumo

Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Francaise d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol. 2002 May;13(5):789-95.Texto completo  Resumo

1. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008 Jun 1;26(16):2767-78. Resumo

2. Williams SM, Killeen AA. Tumor lysis syndrome. Arch Pathol Lab Med. 2019 Mar;143(3):386-93.Texto completo  Resumo

3. McBride A, Westervelt P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol. 2012 Dec 13;5:75.Texto completo  Resumo

4. Howard SC, Trifilio S, Gregory TK, et al. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol. 2016 Mar;95(4):563-73. Resumo

5. McBride A, Trifilio S, Baxter N, et al. Managing tumor lysis syndrome in the era of novel cancer therapies. J Adv Pract Oncol. 2017 Nov-Dec;8(7):705-20.Texto completo  Resumo

6. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004 Oct;127(1):3-11.Texto completo  Resumo

7. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med. 1993 Feb;94(2):133-9. Resumo

8. Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol. 2004 Oct;130(10):623-5. Resumo

9. Habib GS, Saliba WR. Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci. 2002 Mar;323(3):155-7. Resumo

10. Fer MF, Bottino GC, Sherwin SA, et al. Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon. Am J Med. 1984 Nov;77(5):953-6. Resumo

11. Simmons ED, Somberg KA. Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer. 1991 Apr 15;67(8):2062-5. Resumo

12. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma. 2003 Jan;44(1):77-83. Resumo

13. Wössmann W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003 Mar;82(3):160-5. Resumo

14. McCroskey RD, Mosher DF, Spencer CD, et al. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer. 1990 Jul 15;66(2):246-50. Resumo

15. Cany L, Fitoussi O, Boiron JM, et al. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. J Clin Oncol. 2002 Apr 15;20(8):2212. Resumo

16. Montesinos P, Lorenzo I, Martin G, et al. Tumour lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008 Jan;93(1):67-74.Texto completo  Resumo

17. Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet. 2007 Jun 9;369(9577):1923-4. Resumo

18. Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol). 2006 Dec;18(10):773-80. Resumo

19. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors - a case report and review of the literature. Cancer Chemother Pharmacol. 2003 Mar;51(3):187-92. Resumo

20. Alakel N, Middeke JM, Schetelig J, et al. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Onco Targets Ther. 2017 Feb 2;10:597-605.Texto completo  Resumo

21. Mato AR, Riccio BE, Qin L, et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma. 2006 May;47(5):877-83. Resumo

22. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995 Apr;9(2):206-12. Resumo

23. Jeha S. Tumor lysis syndrome. Semin Hematol. 2001 Oct;38(4 Suppl 10):4-8. Resumo

24. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004 Apr 15;116(8):546-54. Resumo

25. Michallet AS, Tartas S, Coiffier B. Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support Cancer Ther. 2005 Apr 1;2(3):159-66. Resumo

26. Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010 May;149(4):578-86.Texto completo  Resumo

27. Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr. 1986 Aug;109(2):292-8. Resumo

28. Hande KR, Hixson CV, Chabner BA. Postchemotherapy purine excretion in patients receiving allopurinol. Cancer Res. 1981 Jun;41(6):2273-9.Texto completo  Resumo

29. Smalley RV, Guaspari A, Haase-Statz S, et al. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000 Apr;18(8):1758-63 (erratum in: J Clin Oncol 2000 May;18(10):2188). Resumo

30. Cheuk DK, Chiang AK, Chan GC, et al. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Databse Syst Rev. 2017 Mar 8;(3):CD006945.Texto completo  Resumo

31. Oldfield V, Perry CM. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. Drugs. 2006;66(4):529-46. Resumo

32. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol. 2001 Oct;38(4 Suppl 10):13-21. Resumo

33. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011 May 12;364(19):1844-54. Resumo

34. American Heart Association. American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 10: special circumstances of resuscitation. Section 11: cardiac arrest associated with life-threatening electrolyte disturbances [internet publication].Texto completo

35. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med.1980 Apr;68(4):486-91. Resumo

36. Krakoff IH, Murphy ML. Hyperuricemia in neoplastic disease in children: prevention with allopurinol, a xanthine oxidase inhibitor. Pediatrics. 1968 Jan;41(1):52-6. Resumo

37. Yarpuzlu A. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta. 2003 Jul 1;333(1):13-8. Resumo

38. Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008 Dec;93(12):1877-85.Texto completo  Resumo

39. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006 Aug;3(8):438-47.Texto completo  Resumo

40. Will A, Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol. 2011 Jul;154(1):3-13.Texto completo  Resumo

41. Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Francaise d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol. 2002 May;13(5):789-95.Texto completo  Resumo

42. Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996 Apr;14(3):1252-61. Resumo

43. Hummel M, Buchheidt D, Reiter S, et al. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol. 2005 Dec;75(6):518-21. Resumo

44. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas [internet publication].Texto completo